Shareholding disclosure

Christopher Brown

Declared position

22.847%

Threshold

Crossed upwards

Timeline

Published

24.12.2025

Transaction

16.12.2025

Voting rights breakdown

Voting rights acquired22.847%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

ZA01-000000000RFU8

Beneficial owner

Christopher Brown

Declared address

Christopher Brown, New York, US

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Christopher Brown

MindMaze Therapeutics Holding SA24.12.2025ZA01-000000000RFU8

Disclosure summary

Christopher Brown disclosed a holding in MindMaze Therapeutics Holding SA on the acquisition side, published by SIX Exchange Regulation on 24.12.2025, at 22.847% of voting rights. Notice category: Single shareholder.

Disclosed position

22.847%

Voting rights acquired

Voting rights acquired22.847%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Christopher Brown disclosed a holding in MindMaze Therapeutics Holding SA, published on 24.12.2025.

Publication date24.12.2025

Transaction date16.12.2025

Issuing companyMindMaze Therapeutics Holding SA

Beneficial ownerChristopher Brown

Declared addressChristopher Brown, New York, US

CategorySingle shareholder

Voting rights acquired22.847%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDZA01-000000000RFU8

Source: SIX Exchange Regulation · Publication date: 24.12.2025

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open